MARQUE DIETZLER: Open Payments
NPI 1073968459 · LOMA LINDA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$655 in 26 payments from 14 companies in 2025. Trend: 2023 $386 · 2024 $905 · 2025 $655
Food & beverage: $556Education: $99
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 8 | $253 |
| GENZYME CORPORATION | 2 | $73 |
| Amgen Inc. | 3 | $52 |
| Lilly USA, LLC | 2 | $42 |
| Arcutis Biotherapeutics, Inc. | 2 | $37 |
| REVANCE THERAPEUTICS, INC. | 1 | $34 |
| UCB, Inc. | 1 | $28 |
| Organon LLC | 1 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
| Incyte Corporation | 1 | $19 |
Products named: DUPIXENT, OTEZLA, MOUNJARO, Zoryve, DAXXIFY, Bimzelx, VTAMA, Sotyktu.
Industry payments across CA — which companies pay providers there.
